Updated:
Ardelyx
Ardelyx was founded in 2007 by a team including Dominique Charmot and Gerrit Klaerner, who spun the company out of their work at the biotech where they...
Ardelyx
Ardelyx was founded in 2007 by a team including Dominique Charmot and Gerrit Klaerner, who spun the company out of their work at the biotech where they identified how sodium-hydrogen exchanger 3 (NHE3) inhibition in the gastrointestinal tract could modulate mineral absorption. Mike Raab joined as president and CEO, setting the company's path toward developing small-molecule therapies that act locally in the gut to manage consequences of chronic kidney disease and irritable bowel syndrome with constipation. The company went public on the NASDAQ in 2014 and has since transitioned into a fully integrated commercial-stage enterprise. The firm's strategy centers on its NHE3 mechanism, which it has deployed across two approved products. Ibsrela (tenapanor) received FDA approval in September 2019 for irritable bowel syndrome with constipation in adults, and Xphozah (tenapanor) was approved in October 2023 as the first and only phosphate absorption inhibitor for adults with chronic kidney disease on dialysis. Ardelyx commercializes both therapies with its own specialty sales force in the United States, targeting approximately 10,000 nephrologists and 12,000 gastroenterologists. The company has established partnerships for ex-U.S. markets, including a licensing agreement with Kyowa Kirin for Ibsrela in Japan and a deal with Shanghai Fosun Pharmaceutical for tenapanor in China. Geographic reach extends across North America, East Asia, and key markets in Europe through royalty-bearing collaborations. Ardelyx employs roughly 239 professionals across its Waltham, Massachusetts headquarters and a second site in Fremont, California. Total revenue for the full year 2024 reached $335.5 million, driven by growing demand for Ibsrela and the accelerating launch of Xphozah. In January 2025, Raab disclosed at the J.P. Morgan Healthcare Conference that the company generated positive cash flow from operations in the fourth quarter of 2024, marking its transition from a cash-consuming R&D organization to a self-sustaining commercial biotech. The company also maintains a discovery-stage pipeline exploring new applications of its NHE3 modulation technology, though the near-term focus remains on maximizing the commercial potential of its two approved products. Ardelyx operates with a rare structure for a commercial-stage biotech — it has avoided large-scale M&A or a major pharmaceutical buyout, choosing instead to build its own patient-facing commercial organization. This go-it-alone nephrology and gastroenterology franchise model is atypical for companies of its size, most of which partner or sell at the first sign of regulatory success. The company's governance reflects continuity: Mike Raab has led the firm for over a decade, and David Mott, a former MedImmune CEO with deep biotech operating experience, serves as chairman, providing the board-level ballast that long-duration independent commercialization demands.
General information
Firm type
other
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
400 Fifth Avenue, Waltham, MA 02451, United States
Additional offices
Fremont, CA, United States
Principals
Mike Raab
President and Chief Executive Officer
David M. Mott
Chairman of the Board
Sector focus
Frequently asked questions
Who runs investment and strategic decisions at Ardelyx?
Mike Raab serves as president and CEO, leading the company since its early development days. Strategic decisions, including capital allocation, commercial buildout, and business development, flow through Raab and the executive committee, with oversight from a board chaired by David Mott, the former CEO of MedImmune. This governance has remained stable for over a decade, a hallmark of the company's independent posture.
What is Ardelyx's core therapeutic mechanism, and how does it differentiate the company?
Ardelyx's platform centers on inhibiting the sodium-hydrogen exchanger 3 (NHE3) in the gastrointestinal tract, a mechanism that modulates paracellular phosphate absorption and fluid secretion without systemic exposure. This local-gut-action approach yields a favorable safety profile compared to systemic phosphate binders or secretagogues. The company has proven the mechanism across two distinct indications — IBS-C and hyperphosphatemia in dialysis — validating a franchise model rather than a single-product bet.
Does Ardelyx commercialize its drugs through partners or its own sales force?
In the United States, Ardelyx markets both Ibsrela and Xphozah through its own specialty sales force that calls on approximately 10,000 nephrologists and 12,000 gastroenterologists. Outside the U.S., the company relies on partnerships — Kyowa Kirin handles Ibsrela in Japan, and Shanghai Fosun Pharmaceutical has rights to tenapanor in China. This hybrid model lets Ardelyx capture the full economics in its highest-value market while leveraging partners abroad.
What is the status of Xphozah's commercial launch?
Xphozah (tenapanor) received FDA approval in October 2023 as the first phosphate absorption inhibitor for adults with chronic kidney disease on dialysis, and Ardelyx began commercial shipment in November 2023. By early 2025, the launch was accelerating, with the company reporting strong demand growth during the J.P. Morgan Healthcare Conference. Xphozah is now the primary near-term growth driver, complementing the established Ibsrela revenue base.
How does Ardelyx generate revenue, and what is its financial position?
The company generates revenue from product sales of Ibsrela and Xphozah in the U.S., alongside milestone and royalty payments from ex-U.S. partnerships with Kyowa Kirin and Fosun Pharma. Total revenue reached $335.5 million for the full year 2024. Critically, CEO Mike Raab announced in January 2025 that Ardelyx had achieved positive cash flow from operations in Q4 2024, marking a significant financial milestone for the formerly R&D-stage company.
Has Ardelyx been an acquisition target, and what is its M&A posture?
Ardelyx has consistently chosen to remain independent, building a commercial organization rather than seeking a buyout — a path that distinguishes it from many small-cap biotechs that sell upon first FDA approval. The company has not publicly positioned itself for sale, and its leadership continuity under Mike Raab suggests a preference for long-term independent value creation. The dual-franchise nephrology and gastroenterology sales force would be difficult for a larger acquirer to replicate quickly, which itself serves as a structural defense.
What is the relationship between the founders and current management?
Scientific founders Dominique Charmot and Gerrit Klaerner identified the NHE3 mechanism at their prior company and co-founded Ardelyx. Charmot left the CEO role early on and Mike Raab, who had been advising the company, stepped in as president and CEO. Charmot and Klaerner are no longer involved in daily operations. Raab has led the company for over a decade, supported by chairman David Mott, providing operational and governance continuity during the transition from R&D to full commercialization.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: